Propella Therapeutics, Inc. presented the results of its recently completed Phase 2 double-blind clinical trial (which examined the tolerability, safety and effects of CGS-200-5 (5% capsaicin topical liquid) on osteoarthritis knee pain) at the 14th Annual Pain Therapeutics Summit on September 21-22, 2020.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-01-15 01:30:302021-09-09 15:25:28Presentation: A Phase 2 Double-Blind Clinical Trial (VZU00025) to Examine the Tolerability, Safety and Effects of CGS-200-0 (Vehicle), CGS-200-1 (1% Capsaicin Topical Liquid) and CGS-200-5 (5% Capsaicin Topical Liquid) on Osteoarthritis Knee Pain (OAKP) (Presented at the 14th Annual Pain Therapeutics Summit on September 21-22, 2020)
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-01-14 15:57:112021-09-09 15:20:20Capsaicin cream 0.025% as Monotherapy for Osteoarthritis: A double-blind study
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-01-14 15:54:092021-09-09 15:20:26Treatment of Arthritis with Topical Capsaicin: A Double-Blind Trial
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-01-14 15:50:552021-09-09 15:20:32Physician/Site Staff Assessments Contribute to High Placebo Response in Rheumatoid Arthritis Clinical Trials
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-01-14 15:46:372021-09-09 15:20:44A review of the high-concentration capsaicin patch and experience in its use in the management of neuropathic pain
Presentation: A Phase 2 Double-Blind Clinical Trial (VZU00025) to Examine the Tolerability, Safety and Effects of CGS-200-0 (Vehicle), CGS-200-1 (1% Capsaicin Topical Liquid) and CGS-200-5 (5% Capsaicin Topical Liquid) on Osteoarthritis Knee Pain (OAKP) (Presented at the 14th Annual Pain Therapeutics Summit on September 21-22, 2020)
/in presentations /by georgePropella Therapeutics, Inc. presented the results of its recently completed Phase 2 double-blind clinical trial (which examined the tolerability, safety and effects of CGS-200-5 (5% capsaicin topical liquid) on osteoarthritis knee pain) at the 14th Annual Pain Therapeutics Summit on September 21-22, 2020.
Capsaicin cream 0.025% as Monotherapy for Osteoarthritis: A double-blind study
/in references (CGS-200-5) /by georgeTreatment of Arthritis with Topical Capsaicin: A Double-Blind Trial
/in references (CGS-200-5) /by georgePhysician/Site Staff Assessments Contribute to High Placebo Response in Rheumatoid Arthritis Clinical Trials
/in references (CGS-200-5) /by georgeDo cultures influence placebo response?
/in references (CGS-200-5) /by georgeA review of the high-concentration capsaicin patch and experience in its use in the management of neuropathic pain
/in references (CGS-200-5) /by george